Natural killer cell

Metagenomi Presents Findings on Three New CRISPR-associated Gene Editing Systems and their Ability to Edit T-Cell and NK-Cell Genomes for Use in Cell Therapy

Retrieved on:

Friday, May 14, 2021

Cost, Ph.D., Senior Director of Biology at Metagenomi, showed that the three CRISPR-associated gene editing systems produced extremely high-frequency gene editing in primary human T cells and NK cells.

Key Points:

Cost, Ph.D., Senior Director of Biology at Metagenomi, showed that the three CRISPR-associated gene editing systems produced extremely high-frequency gene editing in primary human T cells and NK cells.
None of the editing systems adversely affected cell viability.
The precision and activity of the gene editing systems will enable efficient engineering and manufacture of allogenic cell therapies, including next-generation CAR Ts, CAR NKs, and TCR-based T cell therapies.
Our goal is to revolutionize gene editing and unlock its power for the benefit of patients around the world.

Nkarta Reports First Quarter 2021 Financial Results and Business Progress

Retrieved on:

Thursday, May 13, 2021

Immune system, Lymphocytes, Natural killer cell, Expense, Employee stock option

Non-cash stock-based compensation expense included in R&D expense was $1.6 million for the first quarter of 2021.\nG&A Expenses: General and administrative expenses were $5.9 million for the first quarter of 2021.

Key Points:

Non-cash stock-based compensation expense included in R&D expense was $1.6 million for the first quarter of 2021.\nG&A Expenses: General and administrative expenses were $5.9 million for the first quarter of 2021.
Non-cash stock-based compensation expense included in G&A expense was $1.8\xc2\xa0million for the first quarter of 2021.\nNet Loss.
By enlisting this natural source of NK cells, Nkarta starts with bona fide NK cells endowed with inherent tumor-recognizing ability and potent cytotoxic function.
All forward-looking statements contained in this press release speak only as of the date on which they were made.

Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells

Retrieved on:

Thursday, May 13, 2021

Branches of biology, Immune system, Medical specialties, Immunology, Natural killer cell, Antibody-dependent cellular cytotoxicity, T cell, Innate immune system, Macrophage

The preclinical data demonstrated that AFM13 strongly binds to NK cells, including cytokine-activated or cord blood-derived NK (cbNK) cells, resulting in enhanced tumor recognition and antibody-dependent cellular cytotoxicity (ADCC).

Key Points:

The preclinical data demonstrated that AFM13 strongly binds to NK cells, including cytokine-activated or cord blood-derived NK (cbNK) cells, resulting in enhanced tumor recognition and antibody-dependent cellular cytotoxicity (ADCC).
AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages.
The ROCK platform predictably generates customized innate cell engager (ICE\xc2\xae) molecules, which use patients\xe2\x80\x99 immune cells to destroy tumor cells.
For more about the company\xe2\x80\x99s people, pipeline and partners, please visit: www.affimed.com .\nThis press release contains forward-looking statements.

Cytovia Therapeutics Expands Leadership Team

Retrieved on:

Thursday, May 13, 2021

Branches of biology, Biology, Immune system, Induced stem cells, Lymphocytes, Biotechnology, Stem cells, Natural killer cell, Chimeric antigen receptor T cell, Induced pluripotent stem cell, IPSCS

and AVENTURA, Fla., May 13, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic \xe2\x80\x9coff-the-shelf\xe2\x80\x9d gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Jason Aryeh, a long time biotech investor and board director, has been elected to the Cytovia Board of Directors, effective immediately.

Key Points:

and AVENTURA, Fla., May 13, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic \xe2\x80\x9coff-the-shelf\xe2\x80\x9d gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Jason Aryeh, a long time biotech investor and board director, has been elected to the Cytovia Board of Directors, effective immediately.
\xe2\x80\x9cCytovia is uniquely positioned to become a leader in the rapidly growing field of NK (Natural Killer) Cancer Therapeutics.
Cytovia has the potential to positively affect the lives of many patients and consequently create substantial shareholder value in the next few years and beyond."\nMr.
Aryeh has more than twenty years of equity investment experience focused on the life sciences industry.

ILC Therapeutics Announces Board Changes and Funding Round to Accelerate Covid-19 Drug

Retrieved on:

Thursday, May 13, 2021

Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Branches of biology, Medicine, Zoonoses, Immune system, Antiviral drug, Biocides, Virus, COVID-19, Interferon, Natural killer cell, Innate immune system

In some cases (SARS, MERS, Covid-19), viruses can evade the interferon response by delaying the innate immune response.

Key Points:

In some cases (SARS, MERS, Covid-19), viruses can evade the interferon response by delaying the innate immune response.
A therapeutic like Alfacyte\xe2\x84\xa2 can offer enhanced interference to Covid-19 replication in the body and activate the body\xe2\x80\x99s own Natural Killer (NK) cells to fight virus infection.
Alfacyte\xe2\x84\xa2 has the potential to become an important antiviral treatment in the ongoing fight against RVI\xe2\x80\x99s in general and Covid-19 in particular.
It is also a vital treatment for those who are not able to take vaccines or choose not to.

Accelerated Biosciences’ Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and Regenerative Medicine Treatments

Retrieved on:

Tuesday, May 11, 2021

b'Accelerated Biosciences, a regenerative medicine innovator, announced today new data that further demonstrates statistically significant cytolysis with induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells programmed from its ethically sourced human trophoblast stem cells (hTSCs).

Key Points:

b'Accelerated Biosciences, a regenerative medicine innovator, announced today new data that further demonstrates statistically significant cytolysis with induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells programmed from its ethically sourced human trophoblast stem cells (hTSCs).
Pluristyx, a Seattle-based firm supporting drug development, regenerative medicine, and cell and gene therapies, further confirmed Accelerated Biosciences\xe2\x80\x99 hTSC line offers before-unrealized opportunities in cell-specific therapeutics.
We\xe2\x80\x99ve made IPS cells (induced pluripotent stem cells) and NK (natural killer) cells from them, which is the next wave of cells for cell therapies.
Accelerated Biosciences has discovered and is now offering what scientists see as the holy grail of stem cell sources.\xe2\x80\x9d\nProminent biosciences experts have been drawn to Accelerated Biosciences\xe2\x80\x99 cell breakthrough.

Senti Bio to Present Data from CAR-NK Cell Oncology Pipeline at ASGCT 24th Annual Meeting

Retrieved on:

Tuesday, May 11, 2021

Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Immune system, Cell biology, Cell therapy, Haematopoiesis, Gating, Natural killer cell

The presentations provide details of select gene circuit platform technologies being developed by the Company, specifically Logic Gating and Regulator Dial gene circuits.

Key Points:

The presentations provide details of select gene circuit platform technologies being developed by the Company, specifically Logic Gating and Regulator Dial gene circuits.
Logic Gating gene circuits are designed to enable cell and gene therapies to sense inputs, compute decisions and respond to their cellular environments.
NOT GATE gene circuits are designed to widen the therapeutic window by enabling effective killing of cancer cells while preserving healthy cells.
Senti Bio is developing an OR GATE + NOT GATE allogeneic CAR-NK cell therapy that targets and eliminates AML cells while sparing healthy hematopoietic stem and progenitor cells (HSCs/HSPCs).

Acepodia Appoints Thorsten Graef, M.D., Ph.D., as Chief Medical Officer and Michael Brock as Chief Strategy Officer

Retrieved on:

Tuesday, May 11, 2021

Immune system, Branches of biology, Lymphocytes, Natural killer cell, Biology

b'SAN MATEO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Acepodia , a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the appointments of Thorsten Graef, M.D., Ph.D., as chief medical officer and Michael Brock as chief strategy officer.

Key Points:

b'SAN MATEO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Acepodia , a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the appointments of Thorsten Graef, M.D., Ph.D., as chief medical officer and Michael Brock as chief strategy officer.
These key executive hires add to Acepodia\xe2\x80\x99s growing management team, which comprises a deep bench of leading industry experts.
Brock brings to Acepodia more than 20 years of strategic healthcare investment banking experience and leadership, including expertise in industry capital raising, M&A, business development, and strategic analysis.
Its lead product candidate, ACE1702, is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors.

Catamaran Bio’s Scientific Founder Leads Pivotal Advancements in Non-viral Engineering of CAR-NK Cells Using Novel Transposon Technology

Retrieved on:

Tuesday, May 11, 2021

Biotechnology, Health, Genetics, Clinical trials, Oncology, Branches of biology, Biology, Life sciences, Immune system, Biotechnology, Mobile genetic elements, Lymphocytes, Molecular biology, Natural killer cell, Synthetic biology, Transposable element

This is the first presentation of data for this novel transposon technology in NK cells, demonstrating high efficiency transposon integration in primary NK cells, subsequent cell expansion, and in vitro activity of the resulting CAR-NK cells.

Key Points:

This is the first presentation of data for this novel transposon technology in NK cells, demonstrating high efficiency transposon integration in primary NK cells, subsequent cell expansion, and in vitro activity of the resulting CAR-NK cells.
\xe2\x80\x9cThis novel transposon technology demonstrates important capabilities for improved manufacturability, which will be essential in developing safe and effective cell therapies for solid tumors.
Additionally, the TAILWIND Platform includes proprietary, non-viral NK cell engineering technology for efficient modification of NK cells with customized genetic programs enabled by synthetic biology.
For more information, please visit www.catamaranbio.com and follow us on LinkedIn and @CatamaranBio on Twitter.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005312/en/\n'

Acepodia CEO and Co-founder, Sonny Hsiao, Ph.D., to Present at Allogeneic Cell Therapies Summit 2021

Retrieved on:

Monday, May 10, 2021

Branches of biology, Medical specialties, Immune system, Biology, Natural killer cell, Effector cell, T cell

b'Acepodia is a privately held biotechnology company focused on eradicating cancers with potent and targeted first-in-class cell therapies.

Key Points:

b'Acepodia is a privately held biotechnology company focused on eradicating cancers with potent and targeted first-in-class cell therapies.
The company\xe2\x80\x99s next generation allogeneic, off-the-shelf natural killer (NK) cell therapies are based on a proprietary NK cell line (oNK) and NK-like gamma delta T cells that have been selected for their potent anti-tumor activity.
Acepodia\xe2\x80\x99s flexible drug development platform is designed to supercharge immune effector cells\xe2\x80\x99 tumor affinity through its unique Antibody-Cell Conjugation (ACC) technology that links tumor-targeting antibodies to the surface proteins of immune effector cells.
Its lead product candidate, ACE1702, is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors.